Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Waters Corporation. A complete text table follows the diagram.
Adding BD's Biosciences and Diagnostics businesses transformed Waters into a three-engine lab platform where repeat consumable and service demand now supplies 70% of revenue.
Swipe to explore
The Sankey maps reported revenue by monetization type and post-acquisition business. The headline rounds $12.961B of reported acquisition consideration to $13B. The 70% repeat-demand share combines consumables and service; individual purchases are not necessarily subscription revenue.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Instrument systems | 1 | $376M | Installed analytical and diagnostic hardware |
| Consumables | 1 | $543M | Largest revenue stream after the BD deal |
| Service | 1 | $348M | Contracts, maintenance and time-and-materials work |
| Expanded laboratory platform | 2 | $1.3B | Hardware plus repeat laboratory demand |
| Analytical and Materials Sciences | 3 | $686M | Legacy chromatography and mass spectrometry core |
| Biosciences | 3 | $232M | New BD-derived growth engine |
| Advanced Diagnostics | 3 | $349M | Diagnostics expanded 560% year over year |
| From | To | Value |
|---|---|---|
| Instrument systems | Expanded laboratory platform | $376M |
| Consumables | Expanded laboratory platform | $543M |
| Service | Expanded laboratory platform | $348M |
| Expanded laboratory platform | Analytical and Materials Sciences | $686M |
| Expanded laboratory platform | Biosciences | $232M |
| Expanded laboratory platform | Advanced Diagnostics | $349M |